Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1969


Endothelial Dysfunction in Patients With Erectile Dysfunction: A Double-Blind, Randomized-Control Trial Using Tadalafil.

Pattanaik S, Kaundal P, Mavuduru RS, Singh SK, Mandal AK.

Sex Med. 2019 Jan 9. pii: S2050-1161(18)30119-3. doi: 10.1016/j.esxm.2018.11.008. [Epub ahead of print]


The effect of tadalafil on functional capacity and echocardiographic parameters in patients with repaired Tetralogy of Fallot.

Sabri MR, Shoja M, Shoja M, Hosseinzadeh M.

ARYA Atheroscler. 2018 Jul;14(4):177-182. doi: 10.22122/arya.v14i4.1561.


Determination of the Serum Unbound Fraction of Tadalafil in Children with Protein-Losing Enteropathy and Its Specific Binding to Human Serum Proteins in Vitro.

Shigetomi N, Kamiya K, Takamori T, Yoshimura N, Ozawa S, Hirono K, Ichida F, Taguchi M.

Biol Pharm Bull. 2019;42(1):110-115. doi: 10.1248/bpb.b18-00652.


Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis.

Zhang D, Cheng Y, Wu K, Ma Q, Jiang J, Yan Z.

BMC Urol. 2019 Jan 3;19(1):2. doi: 10.1186/s12894-018-0431-7.


Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model.

Fujii S, Yamashita S, Hayashi N, Goto T, Koyama J, Sato T, Shimada S, Kawasaki Y, Izumi H, Kawamorita N, Mitsuzuka K, Ito A, Arai Y.

Prostate. 2018 Dec 28. doi: 10.1002/pros.23759. [Epub ahead of print]


Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome.

Benelli A, Mariani S, Varca V, Gregori A, Barrese F, Cappa M.

Ther Adv Urol. 2018 Oct 26;10(12):377-381. doi: 10.1177/1756287218808677. eCollection 2018 Dec.


[Intense urethrorrhagia after retropubic radical prostatectomy with selective embolization of the internal pudendal artery.]

Caño-Velasco J, Herranz-Amo F, González-Leyte M, Barbas-Bernardos G, Molina Escudero R, Polanco Pujol L, Hernández-Fernández C.

Arch Esp Urol. 2018 Dec;71(10):856-859. Spanish.


Enhancement of the apparent solubility and bioavailability of Tadalafil nanoparticles via antisolvent precipitation.

Rao Q, Qiu Z, Huang D, Lu T, Zhang ZJ, Luo D, Pan P, Zhang L, Liu Y, Guan S, Li Q.

Eur J Pharm Sci. 2019 Feb 1;128:222-231. doi: 10.1016/j.ejps.2018.12.005. Epub 2018 Dec 13.


Voiding behavior and chronic pelvic pain in two types of rat nonbacterial prostatitis models: Attenuation of chronic pelvic pain by repeated administration of tadalafil.

Yamaguchi H, Kurita M, Okamoto K, Kotera T, Oka M.

Prostate. 2018 Dec 14. doi: 10.1002/pros.23750. [Epub ahead of print]


Tadalafil: 15 years' journey in male erectile dysfunction and beyond.

Ahmed NS.

Drug Dev Res. 2018 Dec 13. doi: 10.1002/ddr.21493. [Epub ahead of print]


Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.

Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RMF.

Eur Respir J. 2018 Dec 13. pii: 1801916. doi: 10.1183/13993003.01916-2018. [Epub ahead of print]


Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.

Liao X, Qiu S, Bao Y, Wang W, Yang L, Wei Q.

World J Urol. 2018 Dec 6. doi: 10.1007/s00345-018-2583-1. [Epub ahead of print] Review.


Degree of Planning of Sexual Intercourse Among Men From China, Japan, and Taiwan Taking Medication for Erectile Dysfunction: Findings of an Observational, Cross-Sectional Survey.

Jiann BP, Nakajima K, Dighe S, Harshman-Smith CD, Hassan TA.

Sex Med. 2018 Dec 3. pii: S2050-1161(18)30109-0. doi: 10.1016/j.esxm.2018.10.006. [Epub ahead of print]


Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group.

J Heart Lung Transplant. 2018 Nov 22. pii: S1053-2498(18)31742-X. doi: 10.1016/j.healun.2018.11.006. [Epub ahead of print]


Characterization and Stability of Amorphous Tadalafil and Four Crystalline Polymorphs.

Wei Y, Ling Y, Su M, Qin L, Zhang J, Gao Y, Qian S.

Chem Pharm Bull (Tokyo). 2018;66(12):1114-1121. doi: 10.1248/cpb.c18-00450.


Correction: Tadalafil Augments Tumor-specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma.

Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, Saunders J, Levine M, Tang M, Neuner G, Richmon JD, Blanco R, Agrawal N, Koch WM, Marur S, Weed DT, Serafini P, Borrello I.

Clin Cancer Res. 2018 Dec 1;24(23):6100. doi: 10.1158/1078-0432.CCR-18-3298. No abstract available.


Pharmacoeconomic Review Report: Selexipag (Uptravi) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep.

Supplemental Content

Loading ...
Support Center